Literature DB >> 18622876

Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy.

Zhiwen Yang1, Muhua Yang, Jinnian Peng.   

Abstract

Bovine serum albumin (BSA) nanoparticles containing arsenic trioxide (As(2)O(3)) were prepared by a pH-coacervation method. To investigate the properties of the As(2)O(3)-loaded BSA nanoparticles, a study on drug-to-polymer ratio was done to determine the drug loading (DL), and a H-600 transmission electron microscope (TEM) was used to examine the particle sizes. The results showed that the DL was 27.8% and the average particle size was about 734 nm. The drug release in vitro test was done, which revealed that the drug release was found to provide a slow release after an initial burst release and the cumulative percentage release reached close to 95%. In vitro cytotoxicity test was carried out using APL NB4 cell lines (acute promyelocytic leukemia), and the anticancer efficacy in vivo against mouse H22 hepatoma cells was evaluated on kungming mice. The results indicated that the anticancer efficacy of the As(2)O(3)-loaded BSA nanoparticles was very obvious.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622876     DOI: 10.1080/03639040801926733

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  5 in total

1.  Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.

Authors:  Haimei Chen; Richard Ahn; Jeroen Van den Bossche; David H Thompson; Thomas V O'Halloran
Journal:  Mol Cancer Ther       Date:  2009-06-30       Impact factor: 6.261

2.  Smart Human-Serum-Albumin-As2 O3 Nanodrug with Self-Amplified Folate Receptor-Targeting Ability for Chronic Myeloid Leukemia Treatment.

Authors:  Yongbo Peng; Zilong Zhao; Teng Liu; Xiong Li; Xiaoxiao Hu; Xiaoping Wei; Xiaobing Zhang; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2017-08-04       Impact factor: 15.336

3.  A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.

Authors:  Richard W Ahn; Feng Chen; Haimei Chen; Stephan T Stern; Jeffrey D Clogston; Anil K Patri; Meera R Raja; Elden P Swindell; Vamsi Parimi; Vincent L Cryns; Thomas V O'Halloran
Journal:  Clin Cancer Res       Date:  2010-06-02       Impact factor: 12.531

Review 4.  Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.

Authors:  Mengzhen Yu; Yanwen Zhang; Meirong Fang; Shah Jehan; Wenhu Zhou
Journal:  Pharmaceutics       Date:  2022-03-30       Impact factor: 6.525

5.  Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers.

Authors:  Anam Akhtar; Scarlet Xiaoyan Wang; Lucy Ghali; Celia Bell; Xuesong Wen
Journal:  J Biomed Res       Date:  2017-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.